BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
read more...
Oct 16, 2023
BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
read more...
Oct 13, 2023
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
read more...
Sep 19, 2023
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
read more...
Sep 19, 2023
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
read more...
Aug 31, 2023
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
read more...
Aug 02, 2023
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
read more...
Jul 21, 2023
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
read more...
Jul 12, 2023
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
read more...
Jul 10, 2023
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
read more...
Jul 07, 2023
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
read more...
Jun 15, 2023
BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
read more...
Jun 15, 2023
BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma
read more...
Jun 09, 2023
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
read more...
May 30, 2023
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
read more...
May 25, 2023
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
read more...
May 24, 2023
BeiGene to Present at Upcoming Investor Conferences
read more...
May 17, 2023
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
read more...
May 06, 2023
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
read more...
May 04, 2023
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
read more...
